The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss:

1. Increasing Awareness: Debunking common myths and misconceptions about HS.

2. Building Trust: Strategies for overcoming diagnostic delays and insufficient management.

3. Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities.

4. The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.